Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
Pro Medicus Wins 10-Year, AU$128 Million Cloud Contract With Major US Hospital System
Source: Kapitales Research
Highlights:
A medical imaging software provider signed a 10-year, AU$128 million contract with one of America's largest public hospital systems.
The deal covers a full cloud-based imaging platform, including viewing, workflow and archive tools.
Payments follow a transaction-based model with potential upside, and go-live is targeted for late in the September quarter of 2027.
Healthcare technology investors received a significant US contract update on 20 November 2026. A leading Australian imaging software company confirmed a decade-long agreement with a large New York hospital network. Pro Medicus Limited (ASX: PME) is currently trading at AU$195.37.
A Decade-Long Agreement
On 20 November 2026, Pro Medicus announced that its wholly owned US subsidiary, Visage Imaging, Inc., had signed a 10-year contract worth AU$128 million with NYC Health + Hospitals. The agreement uses a transactional licensing model, so payments are linked to usage rather than a single fixed fee. The company says this structure carries potential upside beyond the headline figure.
What the Platform Covers
The contract is for the company's full stack, which includes Visage 7 Viewer, Visage 7 Workflow and Visage 7 Open Archive. The cloud-based Visage 7 Enterprise Imaging Platform will be rolled out across the hospital system, giving it one unified diagnostic imaging platform. Visage will also move the system's existing image archives from legacy PACS storage into the new Open Archive. The platform will distribute images across the enterprise and connect them to the network's electronic health record.
Rollout Timeline
Planning for the rollout starts immediately and will follow Visage's established cloud-based implementation process. Go-live is targeted for late in the third quarter of the 2027 calendar year.
About the Company
Founded in 1983, Pro Medicus supplies medical imaging software and services to hospitals, imaging centres and healthcare groups worldwide. It acquired Visage Imaging in January 2009 and has offices in Melbourne, Berlin and San Diego.
Outro
The contract adds another large US healthcare customer, and the usage-based model means the final value will depend on how heavily the platform is used. Investors will watch the rollout closely as the 2027 go-live date approaches. This article is general information only and is not financial advice.
Note: All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Pro Medicus Wins 10-Year, AU$128 Million Cloud Contract With Major US Hospital System
Highlights:
Healthcare technology investors received a significant US contract update on 20 November 2026. A leading Australian imaging software company confirmed a decade-long agreement with a large New York hospital network. Pro Medicus Limited (ASX: PME) is currently trading at AU$195.37.
A Decade-Long Agreement
On 20 November 2026, Pro Medicus announced that its wholly owned US subsidiary, Visage Imaging, Inc., had signed a 10-year contract worth AU$128 million with NYC Health + Hospitals. The agreement uses a transactional licensing model, so payments are linked to usage rather than a single fixed fee. The company says this structure carries potential upside beyond the headline figure.
What the Platform Covers
The contract is for the company's full stack, which includes Visage 7 Viewer, Visage 7 Workflow and Visage 7 Open Archive. The cloud-based Visage 7 Enterprise Imaging Platform will be rolled out across the hospital system, giving it one unified diagnostic imaging platform. Visage will also move the system's existing image archives from legacy PACS storage into the new Open Archive. The platform will distribute images across the enterprise and connect them to the network's electronic health record.
Rollout Timeline
Planning for the rollout starts immediately and will follow Visage's established cloud-based implementation process. Go-live is targeted for late in the third quarter of the 2027 calendar year.
About the Company
Founded in 1983, Pro Medicus supplies medical imaging software and services to hospitals, imaging centres and healthcare groups worldwide. It acquired Visage Imaging in January 2009 and has offices in Melbourne, Berlin and San Diego.
Outro
The contract adds another large US healthcare customer, and the usage-based model means the final value will depend on how heavily the platform is used. Investors will watch the rollout closely as the 2027 go-live date approaches. This article is general information only and is not financial advice.
Note: All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au